Study of Epigenetic and Inflammatory Markers of Accelerated Biological Ageing in the Follow-up of Patients With Hodgkin's Lymphoma in Complete Remission for at Least 2 Years
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Enrollment
- 200
- Locations
- 1
- Primary Endpoint
- evaluation of senescence markers (CD57, KLRG1,CD62L, CD45RA)
Study Overview
Brief Summary
Study design: It is a monocentric and exploratory study, experimental on human tissues in vitro which involves the analysis of peripheral blood in patients with Hodgkin's lymphomas with the following characteristics:
- in complete remission for at least two years after first-line therapy with stage IIb, III or IV at onset (Ann Arbor classification).
- newly diagnosed (stage IIb, III or IV, Ann Arbor Classification).
Detailed Description
The study aims to evaluate patients with hodgkin lymphoma in complete remission for at least 2 years and newly diagnosed (stage II b, stage III or stage IV) as they are currently characterised by a long life expectancy during which there is an increased and early incidence of non-neoplastic systemic complications as well as, of course, manifestations of secondary malignancies.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Health Services Research
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •hodgkin lymphoma stage II b, III or IV at onset in remission for at least two years after the first line of therapy for lymphoma
- •Newly diagnosed histologically confirmed stage II b, III or IV patients who require first-line therapy
- •Patients of both sexes aged ≥ 18 years at enrollment
- •Signature of informed consent
Exclusion Criteria
- •Concomitant second neoplasm
Arms & Interventions
hodgkin lymphoma patients in complete remission for at least two years and newly diagnosed
in vitro human tissue testing of peripheral blood in hodgkin lymphoma patients in complete remission for at least two years after first-line therapy with stage II b, III or IV
Intervention: peripheral blood sampling (Other)
Outcomes
Primary Outcomes
evaluation of senescence markers (CD57, KLRG1,CD62L, CD45RA)
Time Frame: through study completion, an average of 2 year
Determine the biological age of patients
DNA methylation (methylation rate)
Time Frame: through study completion, an average of 2 year
Determine the biological age of patients
Secondary Outcomes
- evaluation of senescence markers (CD57, KLRG1,CD62L, CD45RA)(through study completion, an average of 2 year)
- DNA methylation (methylation rate)(through study completion, an average of 2 year)